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Abstract 
Background: Given that viral infections are common triggers for exacerbations of Chronic Obstructive Pulmonary 
Disease (COPD), current clinical guidelines recommend that all patients receive annual influenza vaccinations. A
detailed examination of the immune response to vaccination in COPD has not previously been undertaken, so this 
study aimed to compare immune responses to influenza vaccination between COPD patients and healthy subjects. 
Methods: Twenty one COPD patients and fourteen healthy subjects were recruited and cellular immune function 
was assessed pre- and post- vaccination with trivalent inactivated influenza vaccine. 
Results: One month after vaccination, H1N1 specific antibody titres were significantly lower in COPD patients 
than in healthy controls (p=0.02). Multivariate analysis demonstrated that post vaccination antibody titres were 
independently associated with COPD, but not with age or smoking status. Innate immune responses to the vaccine 
preparation did not differ between the two populations. Serum concentrations of IL-21, a cytokine that is important 
for B cell development and antibody synthesis, were also lower in COPD patients than in healthy subjects (p<0.01). 
In vitro functional differences were also observed, with fewer proliferating B cells expressing CD27 (p=0.04) and 
reduced T-cell IFN-γ synthesis (p<0.01) in COPD patients, relative to healthy subjects. 
Conclusions: In conclusion, COPD was associated with altered immune responses to influenza vaccination 
compared to healthy controls with reductions in both T-cell and B-cell function. These findings provide a foundation 
for future research aimed at optimising the effectiveness of influenza vaccination in COPD. 
Keywords: Chronic Obstructive Pulmonary Disease (COPD); 
Influenza virus; Innate and adaptive immune response; Vaccination 
Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is responsible 
for an increasing burden of disease throughout the world, such that by 
2030, the World Health Organization (WHO) estimates that COPD will 
become the third leading cause of death worldwide [1]. In high income 
countries, tobacco smoke is the biggest risk factor for COPD, while 
in low-income countries, indoor air pollution, especially exposure to 
smoke from cooking stoves, is a major risk factor for COPD [1]. Acute 
exacerbations of COPD frequently result in hospitalization, and are 
responsible for a substantial burden on patients and the health care 
system [2]. These exacerbations are often triggered by bacterial or viral 
infections [3-5], and COPD patients are known to be at particular risk 
of complications arising from seasonal influenza viruses [6]. Finding 
effective ways to prevent respiratory infections in COPD is an important 
priority. 
Given the exacerbations of COPD resulting from viral infections, 
current guidelines recommend that all COPD patients be vaccinated 
against seasonal influenza each year [6-8]; however, the effectiveness 
of this strategy is somewhat controversial. While observational studies 
report less frequent COPD exacerbations, pneumonia, hospitalisations 
and lower mortality rates in vaccine recipients [9-11], there is 
increasing recognition of the ‘healthy user effect’ whereby vaccine 
recipients may also exhibit a variety of lifestyle factors, health seeking 
activities and adherence to medical advice that in themselves lead 
to better health outcomes [11-13]. Some also report that influenza 
vaccination is associated with better health outcomes in summer, 
when influenza virus does not usually circulate, suggesting that the 
apparent benefits reported in observational studies may be subject to 
unidentified confounding factors [14]. A recent Cochrane review noted 
that relatively few Randomized Controlled Trials (RCTs) have studied 
influenza vaccination in COPD [15]. Although two RCTs reported 
that vaccination reduces influenza-related COPD exacerbations, 
both studies were performed in populations with a low rate of prior 
vaccination, and no reduction in hospitalization or mortality was 
observed [16,17]. 
Surprisingly little information is available on the extent to which 
influenza vaccination can induce satisfactory adaptive immune 
responses in COPD. Studies of vaccine immunogenicity have the 
potential to uncover factors associated with a poor vaccine response 
and provide information to guide future research aimed at improving 
vaccine effectiveness, particularly in at-risk patient groups. Following 
vaccination in healthy individuals, virus specific B cells proliferate, 
differentiate into memory B cells and plasma cells and produce 
antibodies to influenza haemagglutinin (HA) and neuraminidase [18]; 
there is strong evidence that the concentration of anti-HA antibodies 
is correlated with protection against influenza [19-21]. T cells are also 
important for host defence against influenza, killing infected target 
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cells, limiting viral replication and providing help to B cells [22,23]. 
Innate immune response to influenza virus leads to the production 
of type I IFN (IFNβ, IFNα) and the expression of interferon inducible 
genes such as MxA and OAS [24]. The cytokines IP-10 and IL-12 are 
also known to be produced after influenza virus exposure [25]. These 
innate factors have a significant role in the vaccine protection mediated 
by adjuvants [26]. 
The objective of this study was to assess the immune response to 
influenza vaccination in COPD patients and healthy controls subjects. 
Persistent colonization of airways by pathogens may contribute to a 
chronic activation state and COPD patients may be less able to mount 
an effective immune response toward Influenza vaccination. Based on 
our initial observation that serum vaccine specific H1N1 antibodies 
titres were lower in COPD patients than in healthy controls, we sought 
to determine the mechanisms underlying the humoral, innate or 
adaptive immune function that might be involved. 
We measured IL-21, a cytokine that is known to have a role in B 
cell development and antibody production [27-29] and which is readily 
measured in serum [30]. Innate immune response of the vaccine 
preparation was assessed in vitro using peripheral blood mononuclear 
cells (PBMC) collected prior to vaccination. B-cell and T-cell function 
were assessed in vitro using vaccine-stimulated PBMC collected before 
and after vaccination. Our findings indicate that COPD is associated 
with reductions in vaccine-specific T cell and B cell function relative 
to healthy individuals while innate immune response to the vaccine 
preparation was unchanged. 
Material and Methods 
Study population 
The study was approved by the Princess Alexandra Hospital Human 
Ethics Committee and written informed consent was obtained from all 
participants who completed an extensive questionnaire and performed 
spirometry according to ATS/ERS criteria. Stable COPD patients with 
an FEV1/FVC ratio <0.7 were recruited from the respiratory outpatient 
clinic, while healthy subjects were spouses of patients and hospital staff. 
Exclusion criteria (for healthy controls and COPD subjects) included 
respiratory infection or COPD exacerbation within the preceding 4 
weeks, malignancy within the preceding 2 years and hypersensitivity to 
egg proteins. Between March and August 2010, all participants received 
a single dose of purified, inactivated, split virion influenza vaccine 
(Fluvax® 2010, Lot B0906-27902, CSL Biotherapies, Parkville, Australia) 
as a deep subcutaneous injection (16 mm needle) in the deltoid region 
of the arm. This vaccine contained the A/California/7/2009 H1N1-like, 
A/Perth/16/2009 H3N2-like and B/Brisbane/60/2008-like influenza 
strains (15 µg HA per strain). 
Blood samples 
Blood was collected from all participants 28 days after vaccination 
(T1; n=14 healthy controls, n=21 COPD patients); some participants 
also had blood collected before vaccination (T0; n=10 healthy controls, 
n=7 COPD patients). Plasma and serum were stored at -20°C while 
PBMC were isolated and used immediately, or cryopreserved in liquid 
nitrogen for later use as previously described [31]. Pre vaccination 
cells were used to assess the innate immune response to the vaccine 
preparation. Post vaccination cells were used to assess the adaptive 
immune response and the memory function by restimulating the cells 
in vitro with the vaccine, to create an artificial re-exposure to the virus. 
Serum influenza specific antibodies and IL-21 
Serum H1N1-specific antibodies (Abs) were measured by 
haemagglutination inhibition assay in a regional reference serology 
laboratory (Prince of Wales Hospital, Randwick NSW). Serum IL-21 
was quantified using a commercial ELISA kit (eBiosciences, San Diego, 
CA) according to the manufacturer’s instructions. Samples were tested 
undiluted; the lower limit of detection was 15.5 pg/ml. 
In vitro cellular immune responses 
PBMC (106 cells/mL) were stimulated in vitro with influenza vaccine 
for five days as detailed in the Supplementary Methods. Supernatant was 
collected at 24 h (IP-10/CXCL10 and IFN-α) and at 5 days (IFN-γ) for 
cytokine measurement by ELISA (see Supplementary Methods). Limit 
of detection were 3.9pg/ml for IP-10, 9.7 pg/ml for IFN-α and 7.8 pg/ 
ml for IFN-γ. Lymphocyte proliferation was assessed by flow cytometry 
with the vital dye Carboxy Fluorescein diacetate Succinimidyl Ester 
(CFSE; Sigma, Taufkirchen, Germany). Briefly, PBMC were labelled 
with CFSE (final concentration of 1 µM) as described elsewhere [32] 
and stimulated in vitro with influenza vaccine for five days. Surface 
staining with anti-human CD19 (eBiosciences) and anti-human CD27 
(Becton Dickenson) was used to identify the phenotype of cells which 
were CFSElow and had thus divided in response to influenza vaccine. 
Additional experimental details are provided in the online data 
supplement. 
RNA from influenza vaccine stimulated PBMC was reverse 
transcribed using Transcriptor first strand cDNA synthesis kit 
(Roche Applied Science), according to manufacturer’s instructions. 
IFN-γ, interferon-inducible Mx A (MxA; also known as Mx1), 
2’,5’-oligoadenylate synthetase (OAS1) and IL-12p35 gene expression 
were investigated by quantitative real time PCR (qPCR), using 
UBE2D2 as the reference gene. UBE2D2 was initially identified as 
a stable reference gene in CD4+ cells [33] and subsequently assessed 
in-house to be stably expressed in total PBMC in the absence and 
presence of influenza vaccine. qPCR was performed using the 
LightCycler 480 (Roche Applied Science, Indianapolis, USA) with 
GoTaq SYBR green (Promega, Madison, USA). Data were analysed 
using the Pfaffl method [34] and results expressed as a ratio of 
stimulated to control (unstimulated) samples, with a fold change of 1 
representing unstimulated expression levels. Primers sequences used 
for amplification are available in Supplementary Table 1. 
Statistical analysis 
Initial statistical analyses were performed using GraphPad Prism 
software, version 6.0. Normality, univariate and multivariate linear 
regression analyses were calculated with SPSS version 17.0 statistical 
Characteristic COPD patients Healthy controls p value 
Subjects 21 14 
Pre vaccination sample (T0) 7 10 
Ages (years; mean[range]) 66(38-80) 54(36-86) 0.01# 
Gender (M/F) 14/7 8/6 0.57& 
Body Mass Index (mean[range]) 26(13-33) 27(21-32) 0.80# 
Previous vaccination 76% (16/5) 79% (11/3) 0.35& 
Co-morbidity* 29% (6/15) 14% (2/12) 0.18& 
Smoking history (current or past) 100% (21/0) 29% (4/10) < 0.001& 
Inhaled steroids 66% (14/7) - -
* Presence of hypertension, hyperlipidemia, diabetes or cardiovascular disease 
# Unpaired t test 
& Chi squared test 
Table 1: Demographic and clinical characteristics. 
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Univariate analysis 
Factor correlation coefficient ρ p value 
Age -0.431 0.011* 
COPD -0.422 0.011* 
Previous vaccination 0.149 0.402 
Inhaled steroids -0.496 0.026* 
Smoking -0.314 0.071 
IL-21 at day 28 0.304 0.091 
Multivariate analysis 
Factor correlation coefficient β p value 
COPD -0.558 0.047* 
*indicates statistical significance 
Table 2: Clinical features associated with post vaccination H1N1 antibody titres. 
related to these other variables. Given this lower immune response 
to the H1N1 strain in the vaccine preparation, we therefore sought to 
evaluate the in vitro immune responses to influenza vaccine in COPD 
patients compared to healthy controls. 
Innate immune responses prior to vaccination 
We next sought to determine if the low post vaccination Ab titres 
in COPD individuals might be related to an impaired innate immune 
response to the vaccine. Thus innate immune responses to the vaccine 
preparation, prior to vaccination, were assessed in vitro. Stimulation 
of PBMC with vaccine for 24 hours induced substantial transcription 
of IFN-β, the interferon stimulated genes MxA and OAS and the Th1 
polarizing cytokine IL-12p35, while analysis of supernatants 24 hours 
software. Kolmogorof-Smirnov testing showed that all the data except 
age and body mass index (BMI) variables were not normally distrib­
uted. Therefore, the non parametric paired Wilcoxon test was used to 
compare pre and post vaccination variables within the same popula­
tion; and the non parametric unpaired Mann Whitney test was used to 
compare variables between COPD subjects and healthy controls within 
the same time point. Parametric unpaired t-tests were used to analyse 
age and BMI (as normally distributed). Differences in seroconversion 
rates were assessed by chi-squared analysis. Univariate and multivari­
ate analysis were used to determine the clinical parameters associated 
with post vaccination serum H1N1 antibody titres. P values ≤ 0.05 were 
considered significant. 
Results 
Subject characteristics 
Demographic characteristics of the subjects are outlined in Table 
1. All subjects were Caucasian, except for three healthy controls (two 
south Asians and one African). 
All COPD patients had a history of current or past smoking, where­
as only four healthy donors were past smokers. COPD subjects were 
somewhat older than the healthy donors (66 ± 11 vs. 54 ± 15 years old; 
p=0.01). Most COPD subjects had moderate, severe or very severe air­
flow obstruction according to current GOLD criteria (Supplementary 
Table 2), while all healthy donors had normal spirometry. Three-quar­
ters of both groups had previously received influenza vaccination. Two 
thirds of COPD patients were using inhaled corticosteroids at the time 
of the study while only one patient was using oral prednisolone. 
Post-vaccination antibody titres 
post-stimulation showed production of high concentrations of IFN-α 
and IP-10 proteins (Table 3). Of the measured innate factors, only IP-10 
was significantly higher in the COPD population compared to healthy 
individuals (Table 3; p=0.04). All other outcomes were similar in COPD 
patients and healthy control subjects. 
Serum IL-21 post-vaccination 
We next sought to examine potential factors involved in adaptive 
immunity that might explain the differences in post-vaccination Ab 
titres between COPD patients and healthy donors. 
Serum IL-21 concentrations were measured in COPD patients and 
healthy subjects 28-days post-vaccination. Significantly lower IL-21 
was detected in COPD patients compared to healthy controls (Figure 
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Figure 1: Serum H1N1 vaccine-specific antibody titres. Sera were collected 
28 days post vaccination. Post vaccination Ab titres were significantly lower 
in COPD subjects (n=21) than in healthy controls (n=14; p=0.02). Horizontal 
lines refer to median values. 
Measurement of post vaccination Influenza A/H1N1 strain-specific 
Ab titres in serum revealed they were significantly lower in COPD 
patients than in healthy controls (Figure 1; median Ab titre COPD=640; 
healthy=1280; p=0.02). Seroconversion, defined as a fold increase ≥ 4 
in Ab titre between pre and four weeks post-vaccination [19], occurred 
in 90% of healthy controls but in only 43% of COPD patients (χ2=4.41; 
p= 0.036; data not shown). Univariate analysis suggested that post 
vaccination Ab titres were significantly associated with age, COPD and 
inhaled steroids but not with previous vaccination status or smoking 
history (Table 2). However, multivariate linear regression showed that 
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0post vaccination Ab titre was independently associated with COPD 
alone, but not with age, smoking history or previous vaccination. Strong 
Healthy           COPD co-linearity between the COPD and inhaled steroid use meant this 
variable could not be used in the multivariate model. Taken together, Figure 2: Post vaccination serum IL-21. Sera were collected 28 days post 
these results imply that the low post vaccination Ab titres in COPD vaccination (T1). Results are shown as median ± IQ; n = 21 COPD subjects 
and 14 healthy controls.individuals were directly related to COPD per se, rather than being 
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Post-vaccination B-cell function in vitro 
In vitro immune functions were examined in a subset of 19 
COPD patients and 12 healthy donors, who were matched for age 
(mean age [range] = 57[37-86] for healthy subjects; mean age [range] 
= 66[38-80] for COPD subjects; p>0.05), in order to provide insight 
into possible mechanisms leading to reduced antibody production in 
COPD. Given the reduced serum IL-21 in COPD, we examined the 
capacity of B-cells to mount a recall response to the vaccine in vitro, 
using PBMC obtained before and 28-days post-vaccination. These 
experiments showed that stimulation of PBMC with influenza vaccine 
for 5-days led to the appearance of a distinct population of proliferating 
B cells (CFSElowCD19+ cells) that express CD27, a marker expressed 
on activated, antigen-experienced B cells (Figure 3a). These CD27+ 
proliferating B cells were more prevalent after vaccination than before 
vaccination for healthy controls (Figure 3b) while an opposite trend 
was observed for COPD subjects. Furthermore, post vaccination, 
fewer CD27+ proliferating B cells were induced in the COPD patients 
compared to healthy controls (Figure 3c and 3d, p=0.04). 
Adaptive ‘cell-mediated’ immune responses to vaccination 
Experiments then examined the capacity of PBMC to produce 
IFN-γ after re-exposure in vitro to the vaccine. PBMC, collected pre 
and post-vaccination, were stimulated with vaccine for 5-days and 
IFN-γ measured in supernatants. PBMC obtained prior to vaccination 
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Figure 3: Frequency of proliferating B-cells expressing CD27 after in vitro vaccine stimulation. PBMC were labelled with CFSE and cultured with influenza vaccine 
for five days. (a) Gating strategy to identify CD19+ proliferating cells (CD19+CFSElow). (b) Pre (T0) and Post (T1) vaccination frequencies of CD27+ cells among 
CD19+CFSElow cells; n=8 healthy controls, n=6 COPD subjects. (c) Examples of CD19 and CD27 expression on CD19+CFSElow cells from PBMC collected post 
vaccination (T1) from 5 healthy controls (upper panel) and 5 COPD patients (lower panel). Percentages of CD19+CFSElow expressing CD27 are indicated in boxes. (d) 
The frequency of post vaccination (T1) CD27+ cells among CD19+CFSElow cells; n=19 COPD subjects and 12 healthy controls. Results are shown as median ± IQ. 
Citation: Burel JG, Nath K, Pritchard AL, White OJ, Davies JM, et al. (2012) Evaluation of Immune Responses to Influenza Vaccination in Chronic 
Obstructive Pulmonary Disease. J Vaccines Vaccin S4:001. doi:10.4172/2157-7560.S4-001 
Page 5 of 7 
              
       
  
 
 
  
 
a	 b 
25000 25000 
20000 20000 
p = 0.94 
p = 0.02 p = 0.025 
p < 0.01 IF
N
-γ
, p
g/
m
l 
15000 
IF
N
-γ
,p
g/
m
l 
15000 
10000 10000 
5000 5000 
0 0 
Influenza - + - + Influenza - + - + 
vaccine vaccine 
Healthy                        COPD	 Healthy                        COPD 
Figure 4: Pre (a) and post (b) vaccination IFN-γ synthesis. PBMC were collected before (T0; n=7 COPD subjects and 10 healthy controls) and after (T1; n=19 COPD 
subjects and 12 healthy controls) vaccination and cultured in vitro for five days in the presence or absence of influenza vaccine. Results are shown as median ± IQ. 
P values refer to the comparison between COPD patients and healthy controls. 
produced similar concentrations of IFN-γ between COPD subjects 
and healthy donors (Figure 4a). Post-vaccination, PBMC from COPD 
subjects produced significantly less IFN-γ than PBMC from healthy 
donors (Figure 4b; p<0.01). The Wilcoxon non-parametric paired test 
showed only vaccine stimulated PBMC from healthy controls produced 
significant higher amount of IFN-γ post vaccination compared to 
baseline (p=0.016 and p=0.81 for healthy controls and COPD subjects, 
respectively). A strong positive correlation was noted between IFN-γ 
and the number of proliferating B cells expressing CD27 in post 
vaccination PBMC (R=0.63, p<0.01). IP-10 production from PBMC 
collected prior to vaccination was inversely proportional to IFN-γ 
production from PBMC collected post-vaccination (R=-0.56, p=0.046); 
i.e. the higher the innate immune response at baseline, the lower the 
IFN-γ recall response post vaccination. 
Discussion 
The objective of this study was to investigate the immune responses 
to influenza vaccination in a small cohort of COPD patients compared 
to healthy controls subjects. Collectively, our data indicate that trivalent 
inactivated influenza vaccine (at a dose of 15 g HA per strain) induced 
an altered humoral and cellular immune response in COPD patients 
relative to healthy control subjects. COPD patients had lower titres of 
H1N1 specific Abs and lower serum IL-21 after vaccination than the 
in the healthy individuals. Taken together, these results suggest that age 
does not explain the reduced H1N1 Ab titres after influenza vaccination 
in COPD subjects. This interpretation is supported by our studies of 
cellular immune function: in a subset of patients and controls who 
were matched for age we observed reduced B-cell and T-cell function 
(Figures 3 and 4). 
“Original Antigenic Sin” (OAS) has been proposed to explain the 
observation that individuals appear to be immunologically imprinted 
according to the first strain of the virus they encounter, often during 
childhood [36]. The Influenza A/H1N1 subtype was the only strain used 
to assess Ab titres in our cohort; however, we doubt that OAS could 
explain the differences in immune responses observed between COPD 
patients and control subjects. Influenza A/H1N1 is the only strain in 
the trivalent influenza vaccine preparation which was circulating before 
1957 and as the majority of subjects in our cohort were born prior to 
this, it is likely that they had been in contact with H1N1 during childhood.
It is noteworthy that measurement of only the Influenza A/H1N1 antibody 
titres in this study does not allow conclusions to be drawn concerning 
the vaccine immunogenicity and its ability to protect against influenza 
infection in COPD patients. These results, however, provided evidence 
of differences in immune responses to vaccination between the study 
groups, prompting us to further investigate innate and adaptive 
healthy controls. Vaccine-stimulated PBMC collected pre and post­
vaccination provided insight into the potential mechanisms leading 
to the differences in antigenic reactivity. Proliferating B cells expressed 
the activation marker CD27 to a lesser extent and the capacity of total 
circulating cells to synthetise IFN-γ was reduced, relative to those from 
healthy subjects. These data suggest a larger study is warranted, as clear 
differences in immune responses to annual influenza vaccination were 
found between patients with COPD and healthy individuals in our 
cohort. 
Healthy COPD p value 
mRNA Fold change; median[range] 
IFNβ 10.78 [0.24-57.1] 4.8 [0.01-37.4] 0.33 
MxA 10.39 [0.33-83.9] 31.25 [0.92-70.0] 0.22 
OAS 16.17 [0.35-58.1] 24.85 [4.45-49.01] 0.37 
IL-12p35 3.28 [0.29-14.98] 4.98 [0.2-10.16] 0.79 
Protein Concentration (pg/ml); median[range] 
IFNα 351.6 [22-660] 81 [50-1880] 0.24 
IP-10 38,016 [0-103020] 124,741 [2570-152540] 0.04 
Multivariate analysis of our data indicated that the association PBMC were stimulated in vitro with influenza vaccine. mRNA and protein levels 
between COPD and post vaccination Ab titres was independent of age. were measured by qPCR and ELISA, respectively. Fold change was calculated 
It is well established that influenza vaccine immunogenicity is lower in 	 as a ratio to baseline (unstimulated PBMCs) whereas concentration refers only to 
protein levels in supernatants stimulated with influenza vaccine. IFN-α and IP-10 healthy elderly people than in healthy younger adults [35]. Although 
were barely detectable or undetectable in unstimulated cultures. Results are shown healthy individuals were younger than the COPD subjects in our study, as median ± IQ; n = 6 COPD subjects and 10 healthy controls.
it is noteworthy that age did not correlate with post vaccination Ab titre Table 3: Innate immune function in healthy subjects and COPD patients. 
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immune responses to influenza vaccination in the context of COPD. 
Surprisingly, we found little evidence that reduced Influenza A/ 
H1N1 antibody titres in COPD might be a consequence of deficient 
innate immune function. We decided to evaluate innate immunity using 
PBMC collected prior to vaccination, as the process of immunization 
should have no impact on the amplitude of the innate immune 
response. Vaccine stimulated cells from COPD patients and healthy 
controls prior to vaccination exhibited similar expression of multiple 
innate immune and antiviral genes and synthesised similar amounts of 
IFN-α protein (Table 3). Synthesis of the chemokine IP-10 was actually 
higher in COPD patients than in healthy controls. Other investigators 
have reported that various cells from COPD patients can produce 
considerable amounts of IP-10 [37,38]. We noted that IP-10 synthesis 
prior to vaccination was inversely proportional to IFN-γ production 
after vaccination, though the explanation for this observation is not 
apparent. 
IL-21 is largely produced by CD4+ T cells [27,28], especially 
follicular helper T-cells, and is thought to play a critical role in lymph 
node germinal centre formation and B cell antibody synthesis [39]. 
Previous studies in HIV infected person have shown that the serum 
IL-21 concentration after influenza vaccination distinguishes vaccine 
responders from non-responders [30]. Although we observed no 
statistical association between serum IL-21 and post-vaccine Ab 
concentrations, the reduced IL-21 may impact on other aspects of 
vaccine immunity in COPD including CD8 T-cell memory, IFN-γ 
synthesis and natural killer cell function [27] . 
In vitro studies with vaccine stimulated cells demonstrated that 
proliferating B-cells from COPD patients expressed less CD27, relative 
to cells from healthy control subjects (Figure 3). CD27 is expressed 
by memory B cells and is further up-regulated in plasma cells [40]. 
Proliferating CD19+CD27+ cells are likely to be highly enriched in 
influenza specific memory B cells. A similar finding was described 
in patients with non-Hodgkin’s lymphoma undergoing influenza 
vaccination, where CD27+ memory B cells were less frequent than in 
healthy controls [41]. Our results therefore indicate that the function of 
the peripheral blood B cell compartment differs between COPD subjects 
and healthy controls. 
Furthermore, we found that vaccine stimulated PBMC from COPD 
subjects synthesized significantly less IFN-γ than PBMC from healthy 
controls. The principal source of this IFN-γ is likely to be activated 
virus specific T cells, rather than natural killer cells. IFN-γ is important 
both for T-cell cytotoxic activity and for enhancing B cell antibody 
production and antibody class-switching; it has been shown that IFN-γ 
production by PBMC 5 days after in vitro stimulation with influenza 
vaccine reflects the quality of the adaptive immune response [42] [43]. 
In our study, the strong correlation between IFN-γ production and 
the number of CD27+ proliferating B cells supports the notion that 
impaired T cell function is contributing to reduced B cell activation. 
We acknowledge that this work is only a small study due to the 
low number of subjects and therefore would need to be replicated in 
a larger cohort. However, based on our statistical analysis, the study 
was adequately powered for the end points that were studied (statistical 
power P = 85% for post vaccination serum H1N1 Ab titres; P=89% for 
post vaccination serum IL-21 titres; P=65% for the frequency of post 
vaccination proliferating B cells expressing CD27; P=99% for post 
vaccination IFN-γ production). 
Current clinical guidelines recommend annual trivalent inactivated 
influenza vaccine for individuals with chronic respiratory diseases such 
as COPD. The findings of the current study do not justify changing these 
recommendations. Though the immune reactivity to influenza vaccine 
was partly reduced in COPD patients, the majority of study participants 
had post-vaccination titres of H1N1 antibodies that are associated with 
seroprotection. Nonetheless we suggest that further investigations are 
warranted to examine the mechanisms behind our observations and 
potential new vaccination approaches in COPD, in order to maximise 
the protection against severe seasonal influenza infections. While live 
attenuated vaccines might be expected to elicit stronger T-cell responses 
than an inactivated vaccine, studies in older adults who have previously 
been vaccinated or exposed to natural influenza infection do not 
support this approach [44]. Increasing the dose of trivalent inactivated 
influenza vaccine might enhance immunogenicity in COPD, especially 
as higher dose vaccine has been shown to improve seroprotection rates 
in severe asthma [45] and in healthy elderly people [46]; adjuvants 
can also improve vaccine immunogenicity [47]. These approaches are 
worthy of further investigation in COPD. 
In conclusion, our study indicates that trivalent inactivated 
influenza vaccine is associated with reduction in serum A/H1N1 
antibody titres and IL-21, impaired B-cell activation and lower IFN-γ 
synthesis after vaccination, thus providing insight into the molecular 
and cellular mechanisms underlying immune function in COPD. 
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